Comparison Chart Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:09 12/12/2025 pm IST			5-day change	1st Jan Change
124.50 ^HKD	+6.05%		+0.32%	+105.11%

12/12	Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab	CI
11/12	Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5d. change	Varia. Jan 1.	1-year change	5-years change	Capi.	ST	MT	LT
	AKESO, INC.	Bio Therapeutic Drugs	+6.05%	+0.32%	+105.11%	+95.60%	+332.29%	1.47TCr